ArticleDiabetology & metabolic syndrome2026
Frailty predicts the onset and dynamic progression of cardio-renal-metabolic multimorbidity: a multistate modeling analysis from the UK Biobank.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFrailty has increasingly been recognized as an important contributor to cardio-renal-metabolic (CRM) diseases. However, most previous studies have focused on isolated outcomes or cross-sectional disease status, lacking a dynamic perspective on disease progression. This study aimed to evaluate the predictive value of frailty for CRM onset and its multistage progression using multistate modeling.
methodsIn this prospective cohort study of 85,003 UK Biobank participants free of CRM diseases at baseline, frailty was categorized as robust, prefrail, and frail. Associations with CRM incidence and progression were examined using Cox proportional hazards and multistate models. The predictive performance of frailty was further assessed using the area under the curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
resultsOver a mean follow-up of 12.0 years, 39.6% of participants were robust, 51.9% were prefrail, and 8.5% were frail. Frailty was independently associated with higher risks of CRM multimorbidity in both incidence and progression analyses. Compared with the robust group, the prefrail group had 28.2%, 36.5%, and 38.0% higher risks of first, double, and triple CRM outcomes, respectively (all p < 0.01), while the frail group had corresponding increases of 81.2%, 118.2%, and 171.1% (all p < 0.001). In multistate models, prefrail participants had 27.5% and 9.1% higher risks of transitioning from a healthy state to the first and from the first to double CRM diseases, respectively (both p < 0.05), whereas the frail group showed respective increases of 78.9% and 32.0% (both p < 0.001). Frailty demonstrated modest discriminative ability for CRM outcomes and provided statistically significant and meaningful improvements in NRI and IDI.
conclusionFrailty was independently associated with both the onset and progression of CRM diseases. Incorporating frailty assessment into risk stratification and preventive frameworks may enhance early identification and mitigation of CRM multimorbidity. Further large-scale prospective studies are warranted to validate these associations and clarify their clinical and public health implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.